Chansaenroj Jira, Lurchachaiwong Woradee, Termrungruanglert Wichai, Tresukosol Damrong, Niruthisard Somchai, Trivijitsilp Prasert, Sampatanukul Pichet, Poovorawan Yong
Center of Excellence in Clinical Virology, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Asian Pac J Cancer Prev. 2010;11(1):117-22.
One of the most common cancers in women worldwide is cervical cancer, with death rates highest in less developed countries, including Thailand. This study was conducted to explore the prevalence of human papillomavirus (HPV) and its related cytological abnormalities among women attending cervical screening clinics in Thailand using the polymerase chain reaction (PCR). LBC specimens (ThinPrep, Hologic, West Sussex, UK) were subjected to PCR of the E1 region to identify the most prevalent HPV types. Information on age and cytology grade was also collected. Among a total of 1,662 women, 29 different HPV types were found and the overall HPV prevalence was 8.7%. HPV prevalence among the general population amounted to 7.8%. The following HPV types were identified: HPV16 (17.9%), HPV90 (16.6%) and HPV71 (10.3%). The rates of other types were as follows; HPV66 (6.9%), HPV52 (6.2%), HPV34 (5.5%), HPV31 (5.3%), HPV42 (4.8%) and HPV39 (3.4%). HPV infection peaked in women aged around 20-39 years and thereafter gradually declined. As expected, HPV DNA can be found in normal cytology specimens. These results which elucidate HPV distribution in Thailand could be useful for vaccine development and the national cervical cancer prevention program.
宫颈癌是全球女性中最常见的癌症之一,在包括泰国在内的欠发达国家死亡率最高。本研究旨在利用聚合酶链反应(PCR)探索泰国宫颈筛查诊所女性中人乳头瘤病毒(HPV)的流行情况及其相关细胞学异常。对液基薄层制片(LBC)标本(英国西萨塞克斯郡Hologic公司的ThinPrep产品)进行E1区域的PCR检测,以确定最常见的HPV类型。还收集了年龄和细胞学分级信息。在总共1662名女性中,发现了29种不同的HPV类型,总体HPV流行率为8.7%。普通人群中的HPV流行率为7.8%。鉴定出以下HPV类型:HPV16(17.9%)、HPV90(16.6%)和HPV71(10.3%)。其他类型的比例如下:HPV66(6.9%)、HPV52(6.2%)、HPV34(5.5%)、HPV31(5.3%)、HPV42(4.8%)和HPV39(3.4%)。HPV感染在20 - 39岁左右的女性中达到峰值,此后逐渐下降。正如预期的那样,在正常细胞学标本中可发现HPV DNA。这些阐明泰国HPV分布情况的结果可能对疫苗研发和国家宫颈癌预防计划有用。